Market Research Logo

FirstWord

FirstWord belongs to a business group that forms one of the world's largest healthcare knowledge networks. Drawing from these knowledge assets, FirstWord reports deliver insight, analysis and the latest thinking on important trends and the most challenging issues affecting the pharmaceutical industry today. Highly-focused, relevant, up-to-date, actionable intelligence - reports that deliver vital intelligence to give a competitive edge.
...Show More ...Show Less

483 Reports from FirstWord

   
  • Medical Affairs Reputations (EU5) [Growth Hormone Deficiency]

    ... growth hormone brands in the EU5 countries (France, Germany, Italy, Spain, and the United Kingdom) are doing a passable job, they may be letting doctors down in other ways. From not valuing doctors’ time enough ... Read More

  • Market Access Impact (US) [NSCLC]

    ... market barriers that prevent oncologists from prescribing competing treatments. Eliminating these barriers won’t be enough for lower-ranked brands to catch up to the market leaders, but it could give a few of them the market ... Read More

  • CLL [2017]

    ... within the next few years? With Imbruvica and Venclexta/Venclyxto on the market, how do key opinion leaders (KOLs) see uptake of these treatments shaping up? Will targeted therapy combinations be able to match the efficacy ... Read More

  • Melanoma [2016]: Bulletin #3

    ... to the US Food and Drug Administration (FDA) for the combination of binimetinib and encorafenib for BRAF-mutant advanced, unresectable or metastatic melanoma; Merck & Co.’s updated longer-term overall survival (OS) data from Phase III KEYNOTE-006 ... Read More

  • Adherence – What Do Pharma Really Know

    ... fundamental patient issue: non-adherence? Is ‘big brother’ technology the answer? Perhaps education is the key? What can be done to ensure patients take drugs as they are intended to be taken and reap the benefits ... Read More

  • NPS+ (US) [Haemophilia A]

    ... this report say they’re satisfied with available brands, and their candid feedback is mostly positive. So why doesn’t that come through in their satisfaction ratings? Only two of the brands we asked them about eked ... Read More

  • NPS+ (US) [Haemophilia B]

    ... satisfaction ratings and low brand loyalty scores mean that brand owners still have plenty of room for improvement. They may want to start by revisiting their messaging strategies. Our research shows that few brand messages ... Read More

  • NPS+ (EU5) [Haemophilia B]

    ... eke out a positive satisfaction score. One way for brands to improve their scores may be to revisit their marketing strategies. Our research shows that brand messages are failing to resonate with doctors. Find out ... Read More

  • MSL stakeholder engagement- meeting expectations

    ... page… The executive summary, taken directly from the report, presents key findings from the research Research objectives and methodologies employed to produce the report Detailed report contents Why this report is important to you 1. ... Read More

  • Market Access Impact (US) [Haemophilia B]

    ... there’s room for brands to grow. To seize that opportunity, you need to understand the market barriers that are preventing doctors from prescribing your brand, and address the ones that are costing you market share. ... Read More

  • Market Access Impact (EU5) [Parkinson's Disease]

    ... surveyed to lose market share while the other half gain. Patient-related barriers are the main culprits, but understanding the unique combination of barriers and competitive dynamics your brand faces is critical if you want to ... Read More

  • RCC: KOL Insight [2017]

    ... stage. KOLs now argue that the first-line treatment of advanced RCC is on the cusp of a second wave of change. At the forefront is a multitude of immunotherapy-based combination regimens that look set to ... Read More

  • Type 2 Diabetes Mellitus [2016]: Bulletin #3

    ... from the Phase IIIb/IV EXSCEL study evaluating the effect of once-weekly Bydureon versus placebo in type-2 diabetics; the FDA’s boxed warning on risks of foot amputations for Johnson & Johnson’s canagliflozin (Invokana/Invokamet) based on data ... Read More

  • MSL stakeholder engagement: meeting expectations

    ... page… 1. The executive summary, taken directly from the report, presents key findings from the research 2. Research objectives and methodologies employed to produce the report 3. Detailed report contents 4. Why this report is ... Read More

  • Medical Affairs Reputations: Type 2 Diabetes Mellitus (US)

    ... US seem to be ticking all the boxes in terms of interaction quality. Notwithstanding this, the diabetologists and primary care physicians we surveyed gave mixed views in terms of performance and satisfaction ratings; while some ... Read More

  • Medical Affairs Reputations: Type 2 Diabetes Mellitus (EU5)

    ... in the EU5 seem to be ticking all the boxes in terms of interaction quality. Notwithstanding this, the diabetologists and primary care physicians we surveyed gave mixed views in terms of performance and satisfaction ratings; ... Read More

  • Market Access Impact (EU5) [MS]

    ... giving market share to most of the brands we surveyed. These market share gains go to 7 of the 11 brands we surveyed, putting the market leaders even further ahead. Meanwhile some brands have a ... Read More

  • NPS+ (US) [NSCLC]

    ... these options are achieving greater levels of loyalty and satisfaction than others – but why? What are the key factors driving physician choice and how does each of the leading brands compare to its competitors? ... Read More

  • COPD [2017]: Bulletin #1

    ... system. The KOLs also imparted their expectations for the US launch of a generic version of GlaxoSmithKline’s Advair Diskus following the acceptance of Sandoz’s Abbreviated New Drug Application (ANDA) for its fluticasone propionate/salmeterol combination product. ... Read More

  • Biosimilars Real World Evidence: Proving the point

    ... by originator companies, often sceptical prescribers must be brought on board, the anxieties of patients reduced, and payer demands for lower prices addressed. Real World Data (RWD) and Real World Evidence (RWE) play a key ... Read More

  • Ulcerative Colitis [2016]: Bulletin #3

    ... the presentation of real-world analyses for Entyvio (vedolizumab) in UC; InDex Pharmaceuticals announcing that it has enrolled the first patient in the Phase IIb CONDUCT trial for Kappaproct (cobitolimod); as well as Amgen announcing the ... Read More

  • Colorectal Cancer [2016]: Bulletin #3

    ... II, CheckMate-142 trial evaluating Opdivo (nivolumab), alone and in combination with Yervoy (ipilimumab), for the treatment of patients with DNA mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC); Roche announcing data ... Read More

  • NPS+ (US) [Growth Hormone Deficiency]

    ... options are achieving greater levels of loyalty and satisfaction than others – but why? What are the key factors driving physician choice and how does each of the leading brands compare to its competitors? NPS+ ... Read More

  • Evidence Matters – Why Pharma Needs to Get Serious about Data

    ... from every quarter lengthens. Against this challenging backdrop, every decision made must be backed up by evidence. But exactly what evidence is required by whom, and how should it be prioritised, gathered, interpreted and leveraged ... Read More

  • What do Patients want from Pharma? The Real Patient-Centric Perspective

    ... The patient voice is becoming increasingly influential and patient groups are looking to pharma for practical and sustained support. But what services do patients want, how do they want them delivered, how do they see ... Read More

3 4 5 6 8 10 11 12

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook